Alan Wu holds the Ph.D. degree and serves as the Chief of clinical chemistry and toxicology at San Francisco General Hospital and as a Professor of laboratory medicine, University of California, San Francisco. He received his B.S. degree in chemistry and biology from Purdue University, West Lafayette, Indiana, and the Ph.D. degree in analytical chemistry from the University of Illinois, Champaign-Urbana, Ill, USA. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. His research interest has been in three areas within the field of clinical chemistry laboratory. He has been involved at the national and international levels with development and use of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, and markers of myocardial ischemia and stroke. He also has a long history of analytical, clinical, and forensic toxicology. In both of these areas, he has coauthored the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. More recently, he has developed research and clinical programs in pharmacogenomics in support of the UCSF clinical pharmacogenomics laboratory. His areas of interest include pharmacogenomics for anticoagulants, especially warfarin, clopidogrel and statins, chemotherapeutics (tamoxifen and irinotecan), drugs that can induce hypersensitivity reactions (abacavir and anticonvulsants), and therapy for hepatis C. More recently, he has been involved with studies involving environmental toxins such as bisphenol A and phthalates.
Biography Updated on 4 September 2011